Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT05129605
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This study aims to define the natural history of men at high genetic risk for prostate cancer on the basis of specific germline genetic mutations, family history, or Black/African ancestry and evaluate the utility of prostate MRI as a screening tool.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostatic Neoplasm
- Prostate Cancer
- BRCA2 Mutation
- BRCA1 Mutation
- ATM Gene Mutation
- MMR Mutation
- Lynch Syndrome
- Genetic Predisposition to Disease
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 35 to 74 years
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Massachusetts General Hospital
- Last updated on ClinicalTrials.gov
- October 9, 2024
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Massachusetts General Hospital · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.